- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01871727
A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma
A Clinical Study to Demonstrate Safety and Efficacy of E7777 in Persistent or Recurrent Cutaneous T-Cell Lymphoma
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
New South Wales
-
Westmead, New South Wales, Australia, 2145
- Westmead Hospital
-
-
Victoria
-
East Melbourne, Victoria, Australia, 3002
- Peter Maccallum Cancer Institute
-
East Melbourne, Victoria, Australia, 3002
- Epworth Healthcare Freemasons
-
-
-
-
-
San Juan, Puerto Rico, 00918
- Auxilio Mutuo Cancer Center
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- University of Alabama at Birmingham, Dermatology at Whitaker Clinic
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- University of Arkansas for Medical Sciences
-
-
California
-
Duarte, California, United States, 91010
- City of Hope Medical Center National Medical Center
-
Orange, California, United States, 92868
- UC Irvine Health-Chao Family Comprehensive Cancer Center
-
Stanford, California, United States, 94305
- Stanford University Cancer Center
-
-
Connecticut
-
New Haven, Connecticut, United States, 06520
- Yale University Cancer Center
-
-
Florida
-
Gainesville, Florida, United States, 32610
- University of Florida
-
Tampa, Florida, United States, 33612
- H. Lee Moffitt Cancer Center
-
Tampa, Florida, United States, 33612
- University of South Florida College of Medicine
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Winship Cancer Institute of Emory University
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Rush University Medical Center
-
Chicago, Illinois, United States, 60612
- Northwestern Memorial Hospital
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Dana Farber Cancer Institute
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- Hackensack University Medical Center
-
-
New York
-
New York, New York, United States, 10032
- Columbia University Medical Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15219
- University of Pittsburgh Medical Center
-
Pittsburgh, Pennsylvania, United States, 15213
- University of PittsburghMedical Center Presbyterian Shadyside
-
-
Texas
-
Houston, Texas, United States, 77030
- The University of TX MD Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Participants must meet all of the following criteria to be included in the study:
- Age greater than or equal to 18 years.
- Histopathologic diagnosis of CTCL (mycosis fungoides [MF] or Sezary Syndrome [SS]), confirmed by skin biopsy, or lymph node, or blood assessment, of current disease.
- CD25 assay-positive tumor, defined as detectable CD25 on greater than or equal to 20% of total lymphoid infiltrate in biopsied lesions by immunohistochemistry.
CTCL disease stage at study entry as follows, according to ISCL/EORTC (Olsen 2011).
- Lead-In Part: Stage IA - IV, except participants with CNS involvement.
- Main Study: Stage I - III
History of prior therapies for CTCL: must have had prior therapy, any number of prior therapies allowed.
Topical treatments (except topical chemotherapy) and steroids are not considered as prior therapies.
A minimum washout period of 4 weeks after previous CTCL therapy is recommended before the first dose of E7777.
Participants must have recovered from any adverse effects from any previous CTCL therapy to Common Terminology Criteria for Adverse Events (CTCAE) Grade <2 before starting study drug. A shorter washout may be allowed if participant is experiencing progressive disease despite ongoing treatment.
- Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2 in the Lead-In Part and performance status of 0 or 1 in the Main Study.
- Life expectancy greater than or equal to 3 months in the Lead-In Part and greater than or equal to 12 months in the Main Study.
Adequate bone marrow reserves as evidenced by:
- platelets greater than or equal to 100,000/mm^3 (100 x 10^9/L)
- clinically stable hemoglobin greater than or equal to 9 gram per deciliter (g/dL) (90 g/L) and hematocrit greater than or equal to 27% without transfusion support
Normal hepatic function as evidenced by:
- bilirubin <= 1.5* upper limit if normal (ULN) and alkaline phosphatase <=3.0*ULN
- aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <= 3.0*ULN
- albumin >= 3.0 g/dL (30 g/L)
- Adequate renal function as evidenced by serum creatinine less than or equal to 1.8 mg/dL (158 umol/L) or calculated creatinine clearance greater than or equal to 50 mL/min (per the Cockcroft-Gault formula) with less than 2+ protein or 24- hour urine creatinine clearance greater than or equal to 50 mL/minute with 24- hour urine protein less than 1gram.
- Provide written informed consent prior to any study-specific screening procedures.
- Females may not be lactating or pregnant at Screening or Baseline
- All females will be considered to be of childbearing potential unless they are postmenopausal or have been sterilized surgically
- Male participants must have had a successful vasectomy (confirmed azoospermia) or they and their female partner must meet the criteria above
Exclusion Criteria
Participants who meet any of the following criteria will be excluded from the study:
- Prior denileukin diftitox therapy
- Use of topical steroids within 14 days of Day 1 of initial therapy is not allowed.Topical steroids or systemic low dose steroids of less than or equal to 10 milligram per day (mg/day) prednisone are allowed in participants with erythroderma who have been on corticosteroids for a prolonged period of time and where discontinuation may lead to rebound flare in disease. The concomitant steroid medication is allowed as long as the type of steroid, route of administration, and steroid dose remain the same as what the participant had been receiving for a prolonged period of time.
- Active malignancy (except for CTCL, definitively treated basal or squamous cell carcinoma of the skin, and carcinoma in-situ of the cervix) within the past 24 months.
- Serious intercurrent illness
- Significant cardiac disease requiring ongoing treatment, including congestive heart failure (CHF), severe coronary artery disease (CAD), cardiomyopathy, uncontrolled cardiac arrhythmia, unstable angina pectoris, or myocardial infarction (MI)
- Significant pulmonary symptoms or disease
- History of uncontrolled seizure disorder or active central nervous system disease
- Major surgery within 2 weeks of study enrollment
- Significant or uncontrolled infections requiring systemic anti-infective therapy
- Known human immunodeficiency virus (HIV) infection; known active hepatitis B or hepatitis C infection
- Females who are pregnant (positive urine test) or breastfeeding
- Any history of a medical condition or a concomitant medical condition that, in the opinion of the investigator, would compromise the participant's ability to safely complete the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: E7777
|
administered by intravenous (i.v.) infusion over 60 minutes (+/-10 minutes) on 5 consecutive days during every cycle of 21 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Dose-limiting toxicities (DLTs) in the Lead-In Part
Time Frame: Cycle 1 (21 days)
|
Cycle 1 (21 days)
|
Maximum Tolerated Dose (MTD) in the Lead-In Part
Time Frame: Up to12 months
|
Up to12 months
|
ORR in the Main study
Time Frame: Day 1 until disease progression/recurrence, or up to 30 months
|
Day 1 until disease progression/recurrence, or up to 30 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Duration of Response (DOR)
Time Frame: Day 1 until disease progression/recurrence, or up to 12 months (Lead-in Part) and Day 1 until disease progression/recurrence, or up to 30 months (Main Study)
|
Day 1 until disease progression/recurrence, or up to 12 months (Lead-in Part) and Day 1 until disease progression/recurrence, or up to 30 months (Main Study)
|
Time to Response (TTR)
Time Frame: Up to 12 months (Lead-In Part) and up to 30 months (Main study)
|
Up to 12 months (Lead-In Part) and up to 30 months (Main study)
|
ORR
Time Frame: Day 1 until disease progression/recurrence, up to 12 months (Lead-in Part) and Day 1 until disease progression/recurrence, up to 30 months (by using Prince (2010) criteria in Main Study)
|
Day 1 until disease progression/recurrence, up to 12 months (Lead-in Part) and Day 1 until disease progression/recurrence, up to 30 months (by using Prince (2010) criteria in Main Study)
|
Number of Participants with Any Adverse Event and Any Serious Adverse Event (SAE)
Time Frame: From first dose of the study drug until 30 days after the last dose, or up to 30 months
|
From first dose of the study drug until 30 days after the last dose, or up to 30 months
|
Maximum Drug Concentration (Cmax)
Time Frame: Cycles 1, 3, 5 Day 1: pre-dose-300 minutes post infusion stop (Lead-in part and for first 12 participants in the Main study) (Cycle length is equal to [=] 21 days)
|
Cycles 1, 3, 5 Day 1: pre-dose-300 minutes post infusion stop (Lead-in part and for first 12 participants in the Main study) (Cycle length is equal to [=] 21 days)
|
Area Under the Curve from Time 0 to Time t (AUC[0-t])
Time Frame: Cycles 1, 3, 5 Day 1: pre-dose-300 minutes post infusion stop (Lead-in part and for first 12 participants in the Main study) (Cycle length=21 days)
|
Cycles 1, 3, 5 Day 1: pre-dose-300 minutes post infusion stop (Lead-in part and for first 12 participants in the Main study) (Cycle length=21 days)
|
Area Under the Curve from Time 0 to Time Infinity (AUC[0-inf])
Time Frame: Cycles 1, 3, 5 Day 1: pre-dose-300 minutes post infusion stop (Lead-in part and for first 12 participants in the Main study) (Cycle length=21 days)
|
Cycles 1, 3, 5 Day 1: pre-dose-300 minutes post infusion stop (Lead-in part and for first 12 participants in the Main study) (Cycle length=21 days)
|
Terminal Elimination Half-life (t1/2)
Time Frame: Cycles 1, 3, 5 Day 1: pre-dose-300 minutes post infusion stop (Lead-in part and for first 12 participants in the Main study) (Cycle length=21 days)
|
Cycles 1, 3, 5 Day 1: pre-dose-300 minutes post infusion stop (Lead-in part and for first 12 participants in the Main study) (Cycle length=21 days)
|
Time to Reach Maximum (peak) Concentration After Drug Administration (Tmax)
Time Frame: Cycles 1, 3, 5 Day 1: pre-dose-300 minutes post infusion stop (Lead-in part and for first 12 participants in the Main study) (Cycle length=21 days)
|
Cycles 1, 3, 5 Day 1: pre-dose-300 minutes post infusion stop (Lead-in part and for first 12 participants in the Main study) (Cycle length=21 days)
|
Total Body Clearance (CL)
Time Frame: Cycles 1, 3, 5 Day 1: pre-dose-300 minutes post infusion stop (Lead-in part and for first 12 participants in the Main study) (Cycle length=21 days)
|
Cycles 1, 3, 5 Day 1: pre-dose-300 minutes post infusion stop (Lead-in part and for first 12 participants in the Main study) (Cycle length=21 days)
|
Volume of Distribution at Steady State (Vdss)
Time Frame: Cycles 1, 3, 5 Day 1: pre-dose-300 minutes post infusion stop (Lead-in part and for first 12 participants in the Main study) (Cycle length=21 days)
|
Cycles 1, 3, 5 Day 1: pre-dose-300 minutes post infusion stop (Lead-in part and for first 12 participants in the Main study) (Cycle length=21 days)
|
Percentage of Participants Testing Positive for Anti-E7777 and Anti-IL-2 Antibodies
Time Frame: Da y 1 of Cycles 1, 2, 3, 5, and 8 (for Anti-E7777 and Anti-IL-2); Anti-IL-2 is to be tested at 6 month, 1 year, and thereafter every year until antibody levels decrease to baseline levels
|
Da y 1 of Cycles 1, 2, 3, 5, and 8 (for Anti-E7777 and Anti-IL-2); Anti-IL-2 is to be tested at 6 month, 1 year, and thereafter every year until antibody levels decrease to baseline levels
|
Number of Participants with Skin Response in the Main Study
Time Frame: Day 1 until disease progression/recurrence, or up to 30 months
|
Day 1 until disease progression/recurrence, or up to 30 months
|
Duration of Skin Response in the Main Study
Time Frame: Day 1 until disease progression/recurrence, or up to 30 months
|
Day 1 until disease progression/recurrence, or up to 30 months
|
Time to Skin Response in the Main Study
Time Frame: Up to 30 months
|
Up to 30 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- E7777-G000-302
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Persistent or Recurrent Cutaneous T-Cell Lymphoma
-
Legend Biotech USA IncActive, not recruitingT-Cell Lymphoma | Peripheral T-Cell Lymphoma Refractory | Cutaneous T-Cell Lymphoma Refractory | Cutaneous T-Cell Lymphoma Recurrent | Peripheral T-Cell Lymphoma RecurrentUnited States
-
John ReneauActive, not recruitingRecurrent T-Cell Non-Hodgkin Lymphoma | Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma | Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma | Primary Cutaneous Anaplastic Large Cell Lymphoma | Refractory Primary Cutaneous T-Cell Non-Hodgkin... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingRefractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma | Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma | Refractory Cutaneous T-Cell Non-Hodgkin LymphomaUnited States
-
John ReneauRecruitingRecurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Recurrent Adult T-Cell Leukemia/Lymphoma | Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Refractory Adult T-Cell Leukemia/LymphomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingSezary Syndrome | Recurrent Mycosis Fungoides | Refractory Mycosis Fungoides | Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma | Folliculotropic Mycosis Fungoides | Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified | Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma | Refractory Cutaneous...United States
-
National Cancer Institute (NCI)TerminatedRecurrent Cutaneous T-cell Non-Hodgkin Lymphoma | Stage I Cutaneous T-cell Non-Hodgkin Lymphoma | Stage II Cutaneous T-cell Non-Hodgkin LymphomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Recurrent Grade 3a Follicular Lymphoma | Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Recurrent Mycosis Fungoides | Recurrent Primary Cutaneous... and other conditionsUnited States, Canada
-
National Cancer Institute (NCI)TerminatedRecurrent Cutaneous T-cell Non-Hodgkin Lymphoma | Recurrent Mycosis Fungoides/Sezary SyndromeUnited States
-
National Cancer Institute (NCI)CompletedAnaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Recurrent Adult T-cell Leukemia/Lymphoma | Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma | Recurrent Mycosis Fungoides/Sezary Syndrome | Small Intestine Lymphoma | Stage III Cutaneous T-cell Non-Hodgkin Lymphoma | Stage III Mycosis... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Angioimmunoblastic T-Cell Lymphoma | Recurrent Mycosis Fungoides | Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Refractory Angioimmunoblastic T-Cell Lymphoma | Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Refractory Mycosis Fungoides | Refractory Anaplastic... and other conditionsUnited States
Clinical Trials on E7777 9 mcg/kg
-
Janssen Pharmaceutical K.K.Completed
-
Mayo ClinicRecruitingPain ControlUnited States
-
Cara Therapeutics, Inc.CompletedPruritus | Uremic PruritusUnited States
-
MedImmune LLCCompletedChronic Lymphocytic Leukemia | Non-Hodgkin LymphomaUnited States, Poland
-
MedImmune LLCCambridge Antibody TechnologyTerminatedLeukemia, Lymphoma, Chronic Lymphocytic | Leukemia, Prolymphocytic Leukemia, Small | Lymphocytic Lymphoma, Moxetumomab PasudotoxUnited States, Poland
-
Protalex, Inc.CompletedArthritis, RheumatoidUnited States
-
Cara Therapeutics, Inc.Completed
-
Cara Therapeutics, Inc.CompletedUremic PruritusUnited States, Czechia, Hungary, Poland
-
Cara Therapeutics, Inc.CompletedUremic PruritusUnited States
-
Cara Therapeutics, Inc.CompletedUremic PruritusUnited States, Canada, Czechia, Australia, Germany, Hungary, Korea, Republic of, New Zealand, Poland, Taiwan, United Kingdom